News & Updates

First-line durvalumab plus carboplatin/paclitaxel and bevacizumab followed by durvalumab, bevacizumab plus olaparib maintenance significantly improves progression-free survival (PFS) in patients with newly diagnosed non-BRCA-mutated advanced ovarian cancer, when compared with carboplatin/paclitaxel and bevacizumab followed by bevacizumab, as shown in the DUO-O study.

Imlunestrant-based regimens provide clinically meaningful improvements in progression-free survival (PFS), as well as overall survival (OS), in endocrine-pretreated patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC), results of the phase III EMBER-3 trial have shown.

A study from Israel presented at ELCC 2026 supports the role of glucose control as a modifiable host factor that could improve the effectiveness of immune checkpoint inhibitors in the treatment of non-small cell lung cancer (NSCLC).

Data from a large, prospective, non-randomized study in China show that one-time low-dose computed tomography (LDCT) screening is associated with a significant reduction in lung cancer mortality in a non–risk-based population, including those who have never smoked.